Health Care·Biotechnology·$40.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.20 | N/A | +29.58% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.20 | N/A | +29.58% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding market conditions. They reiterated their commitment to long-term strategies while acknowledging short-term difficulties.
Management highlighted ongoing challenges in the market.
They emphasized a focus on long-term growth despite current setbacks.
Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock fell by 2.3% in reaction, likely due to the lack of revenue information and no guidance for the future. Investors may be concerned about the company's ability to navigate current market challenges without clear direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
EDWARDS LIFESCIENCES
Feb 4, 2013